Related Experiment Video
Updated: Jun 10, 2026
08:07
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
Development of new HLA-B*3505 genotyping method using Invader assay
Naoya Hosono1, Soranun Chantarangsu, Kazuma Kiyotani
1Laboratory for Genotyping Development, University of Tokyo, Japan. nhosono@src.riken.jp
Pharmacogenetics and Genomics
|August 4, 2010
Summary
A new genotyping method accurately identifies HLA-B*3505, a biomarker for nevirapine-induced skin rash. This simple, rapid assay aids pharmacogenetic testing in the Thai population.
Area of Science:
- Pharmacogenetics
- Immunogenetics
- Molecular Diagnostics
Background:
- Specific human leukocyte antigen (HLA) alleles are strongly associated with drug hypersensitivity.
- HLA-B*3505 has been identified as a genetic biomarker for nevirapine-induced skin rash in the Thai population.
Purpose of the Study:
- To develop a novel and efficient genotyping method for HLA-B*3505.
- To validate the new method for pharmacogenetic testing of nevirapine-induced skin rash.
Main Methods:
- Developed a genotyping assay combining the Universal Invader assay and sequence-specific primer PCR.
- Selected two highly discriminative single nucleotide polymorphism (SNP) sites (rs1140412 and rs4997052) from sequence alignment of 68 HLA-B alleles.
- Tested the assay on 324 Thai individuals, analyzing fluorescence intensities.
Main Results:
- The assay successfully discriminated between HLA-B*3505-positive and -negative samples.
- Achieved 100% concordance with sequence-based typing methods.
- Demonstrated the assay's simplicity and speed.
Conclusions:
- The developed HLA-B*3505 genotyping method is accurate, simple, and rapid.
- This assay is a valuable tool for pharmacogenetic testing to predict nevirapine-induced skin rash.
- Facilitates personalized medicine approaches in drug hypersensitivity management.
